NOVARTIS

Cosentyx Derm - Digital dosing schedule - HCP

Prescribing information

Image

Image

Digital dosing schedule

Cosentyx® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy.[1]

Full indications for Cosentyx can be found here.

Please refer to the Summary of Product Characteristics (SmPC) for further information. The UK SmPC can be found **here**.

Help your newly initiated Cosentyx patients keep track of their treatment with a digital dosing schedule. As a healthcare professional, you can download the relevant documents and fill in the patient’s planned injection dates.

Share the completed file with your patients and they can simply tick the circles after they administer their Cosentyx dose, as shown in the example below:

Image

Cosentyx® secukinumab

NOVARTIS

Cosentyx (secukinumab) patient dosing schedule for Psoriasis

Name: _____ Prescribed dose: _____ mg

Keep track of your Cosentyx treatment using the dosing schedule below. Your healthcare professional should have already entered **your planned injection dates.**

You can **tick the clickable circles** after administering Cosentyx*, or alternatively print the document to keep track by hand.

*Please note that the clickable function may not work on some devices.

Tick the circle when you've had your treatment on the planned date.

Your healthcare professional has already entered your planned injection dates here.



Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.

This leaflet is intended for UK patients who have been prescribed Cosentyx. Not for further distribution.

This resource has been produced and funded by Novartis Pharmaceuticals UK Ltd.
UK | March 2023 | 252771-1

Choose the right schedule for your patients based on Cosentyx dosage and indication, by

using the resources below.

Please note that these resources are designed for optimal use on desktop or tablet. Functionality may be restricted on some devices, including mobile.

Do not share links to this website or screenshots with patients as this website is intended for healthcare professionals only.

Image



Adult psoriasis (PsO) dosing

PDF
Download
Image

≥90 kg Adult psoriasis (PsO)

PDF
Download
Image

Cosentyx® secukinumab

NOVARTIS

Cosentyx (secukinumab) patient dosing schedule for paediatric psoriasis

Name: _____ Prescribed dose: _____

Keep track of your Cosentyx treatment using the dosing schedule below. Your healthcare professional should have already entered **your planned injection dates**.

You can **tick the clickable circles** after administering Cosentyx*, or alternatively print the document to keep track by hand.

*Please note that the clickable function may not work on some devices.

Tick the circle when you've had your treatment on the planned date.



Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.

This leaflet is intended for UK patients who have been prescribed Cosentyx. Not for further distribution.

This resource has been produced and funded by Novartis Pharmaceuticals UK Ltd.
UK | March 2025 | 259242-1

Paediatric psoriasis (PsO)

PDF
Download

Image

PsO dosing

Therapeutic indications[1]

Cosentyx is indicated for the treatment of moderate to severe PsO in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active PsA in adult patients (alone or in combination with MTX) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active AS in adults who have responded inadequately to conventional therapy; active nr-axSpA with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe HS (acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active ERA in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active JPsA in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.[1]

AS, ankylosing spondylitis; ERA, enthesitis-realted arthritis; HS, hidradenitis suppurativa; JPsA, juvenile psoriatic arthritis; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, plaque psoriasis; SmPC, summary of product characteristics.

Reference

1. Cosentyx® (secukinumab) Summary of Product Characteristics.

UK | January 2025 | FA-11328315

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.
